<DOC>
	<DOCNO>NCT01813929</DOCNO>
	<brief_summary>Insulin resistance ( IR ) important contributor increase cardiovascular disease risk type 1 diabetes ( T1D ) . The purpose study measure effect metformin insulin sensitivity , vascular function compliance , mitochondrial function T1D . The long term goal identify novel non-glycemic approach manage cardiovascular disease risk T1D . The result study may validate novel approach T1D treatment could significantly improve current management cardiovascular disease risk high risk population .</brief_summary>
	<brief_title>Effect Metformin Vascular Mitochondrial Function Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age 2059 year age , Type 1 diabetes base antibodypositivity , rapid persistent conversion insulin requirement diagnosis , absent Cpeptide , DKA diagnosis , clinical course consistent T1D , HbA1c 6.0 9.5 , Willing able commit two 6 weeklong period blind medication follow hyperinsulinemic euglycemic clamp , vascular testing , muscle biopsy . Any comorbid condition associate : inflammation , insulin Resistance , dyslipidemia include : 1. cancer , 2. heart failure , 3. active end stage liver disease , 4. kidney disease , 5. rheumatological disease ; Tobacco use ; Pregnancy woman breastfeed ; Steroid use ; Scheduled strenuous physical activity &gt; 3 day week ; Angina , know CAD , cardiovascular pulmonary disease ; A history COPD asthma ; Presence systolic blood pressure &gt; 190 rest &gt; 250 exercise , diastolic pressure &gt; 95 rest &gt; 105 exercise ; Untreated thyroid disease ; Proteinuria ( urine protein &gt; 200 mg/dl ) creatinine &gt; 1.5 mg/dl ( male ) 1.4 mg/dL ( female ) , suggestive severe renal disease ; Severe Proliferative retinopathy ; Niacin treatment ; Administration experimental agent T1D within 30 day prior screen ; Recent ( prior 6 month ) current metformin thiazolidenedione use ; Hypoglycemia unawareness recurrent severe hypoglycemia ( symptoms hypoglycemia FSBS &lt; 40 episode severity &gt; 1 per week ) ; Weight instability ( weight change &gt; 5 % last 6 month ) ; History organ transplant , include islet cell transplant ; Current prior infection HIV , hepatitis B hepatitis C hepatic insufficiency ( AST ALT &gt; 2x upper limit normal ) ; Any condition , medical otherwise would , opinion investigator , prevent complete participation study , would pose significant hazard subject ; History substance abuse within 12 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Insulin</keyword>
	<keyword>Metformin</keyword>
	<keyword>Vascular</keyword>
	<keyword>Vessels</keyword>
	<keyword>Type 1</keyword>
</DOC>